Lower COVID-19 Vaccine Sales Estimated Amid Less Severe Omicron Variant: Bloomberg


27% profit every 20 days?

This is what Nic Chahine averages with his option buys. Not selling covered calls or spreads… BUYING options. Most traders don’t even have a winning percentage of 27% buying options. He has an 83% win rate. Here’s how he does it.


According to an analytics firm, Airfinity Ltd, evidence that omicron causes less-severe disease than earlier COVID-19 variants is expected to lower the growth in vaccine sales this year.

ENTER TO WIN $500 IN STOCK OR CRYPTO

Enter your email and you'll also get Benzinga's ultimate morning update AND a free $30 gift card and more!

  • Citing Airfinity, Bloomberg reports that COVID-19 vaccine sales, excluding China and India, will increase to about $85 billion in 2022, down about 28% from an earlier estimate of $118 billion.
  • The analytics firm said that the revision was also due to lower prices paid by poorer nations for the shots.
  • Related: Federal Health Officials Say Omicron-Targeted Shots May Not Be Necessary: WSJ.
  • Demand for doses is still rising, and booster programs in high-income countries will be a key driver, according to Airfinity, which estimates that sales will climb almost 30% in 2022 from about $66 billion last year. 
  • Moderna Inc (NASDAQ:MRNA) could record about $26 billion in sales in 2022, while Pfizer Inc (NYSE:PFE) and its partner BioNTech SE (NASDAQ:BNTX) may clock about $43 billion. 
  • AstraZeneca Plc (NASDAQ:AZN) is expected to generate $4.3 billion in vaccine revenue. 
  • The firm's estimates differ from that of the drugmakers themselves. 
  • Pfizer has forecast $31 billion in 2022 COVID-19 vaccine sales. 
  • Prelim COVID-19 vaccine sales for Moderna stand at $18.5 billion, along with a potential $3.5 billion from boosters and other purchases. 
  • Price Action during the premarket session on the last check Friday:
    • MRNA stock is down 1.27% at $165.40 
    • PFE shares are down 0.30% at $53.89 
    • BNTX stock is down 2.15% at $153.16 
    • AZN shares are down 0.48% at $59.88 

27% profit every 20 days?

This is what Nic Chahine averages with his option buys. Not selling covered calls or spreads… BUYING options. Most traders don’t even have a winning percentage of 27% buying options. He has an 83% win rate. Here’s how he does it.


Posted In: BiotechEarningsNewsGuidanceHealth CareGeneralBriefsCOVID-19 CoronavirusCOVID-19 Vaccine